Evidence map›Paper›PMID 42231728›Full record

ArticleAngewandte Chemie (International ed. in English)2026

Enantioselective Synthesis of Atropisomeric 1,3-Dienes via Platinum-Catalyzed Hydrosilylation of 1,3-Enynes.

Qimin Wu, Xuanyi Li, Weiyuan Wang, Jing Zhong, Aijun Lin, Qiuyu Li, Shang Gao, Hequan Yao

Abstract read
In one paragraph

Article in Angewandte Chemie (International ed. in English), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Qimin WuState Key Laboratory of Natural Medicines (SKLNM) and Department of Medicinal Chemistry, School of Pharmacy, China Pharmaceutical University, Nanjing, People's Republic of China.
Xuanyi LiState Key Laboratory of Natural Medicines (SKLNM) and Department of Medicinal Chemistry, School of Pharmacy, China Pharmaceutical University, Nanjing, People's Republic of China.
Weiyuan WangState Key Laboratory of Natural Medicines (SKLNM) and Department of Medicinal Chemistry, School of Pharmacy, China Pharmaceutical University, Nanjing, People's Republic of China.
Jing ZhongState Key Laboratory of Natural Medicines (SKLNM) and Department of Medicinal Chemistry, School of Pharmacy, China Pharmaceutical University, Nanjing, People's Republic of China.
Aijun LinState Key Laboratory of Natural Medicines (SKLNM) and Department of Medicinal Chemistry, School of Pharmacy, China Pharmaceutical University, Nanjing, People's Republic of China.ORCID https://orcid.org/0000-0001-5786-4537
Qiuyu LiState Key Laboratory of Natural Medicines (SKLNM) and Department of Medicinal Chemistry, School of Pharmacy, China Pharmaceutical University, Nanjing, People's Republic of China.ORCID https://orcid.org/0009-0007-3925-5456
Shang GaoState Key Laboratory of Natural Medicines (SKLNM) and Department of Medicinal Chemistry, School of Pharmacy, China Pharmaceutical University, Nanjing, People's Republic of China.ORCID https://orcid.org/0000-0001-8166-5503
Hequan YaoState Key Laboratory of Natural Medicines (SKLNM) and Department of Medicinal Chemistry, School of Pharmacy, China Pharmaceutical University, Nanjing, People's Republic of China.ORCID https://orcid.org/0000-0003-4865-820X

Funding

China Postdoctoral Science Foundation 2024M763657Fundamental Research Funds for the Central Universities 2632025PY03Innovation and Entrepreneurship (Shuangchuang) Program of Jiangsu Province (2024)National Natural Science Foundation of China 22501296National Natural Science Foundation of China NSFC22371299Natural Science Foundation of Fuyang Normal University FYKFKT24004Natural Science Foundation of Jiangsu Province BK20251564Postdoctoral Fellowship Program of CPSF GZB20250246
6 · The paper itself

Abstract

The enantioselective synthesis of novel atropisomeric architectures represents a key driving force in the advancement of functional materials, drug discovery, and asymmetric catalysis. While great progress has been made in the enantioselective synthesis of biaryl atropisomers, the catalytic enantioselective synthesis of atropisomeric acyclic 1,3-dienes is still elusive due to the inherently low rotational barrier of the C-C bonds. Herein, we report a platinum-catalyzed enantioselective hydrosilylation of enynes. Using a monophosphine ligand L1, the atropisomeric 1,3-dienes are constructed in good yield with enantioselectivity and excellent regio- and E-selectivity. Density functional theory (DFT) calculations are conducted to elucidate the origin of the regio- and enantioselectivity. Crucially, the basic additive such as KOH and K

Indexed as

atropisomeric 1,3‐dienesenantioselectiveenyneshydrosilylationregioselective

Identifiers

PMID42231728
PMCPMC13427112

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.